Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Department of Medicine A, Hematology and Oncology, Münster University Hospital, Münster, Germany.
Leukemia. 2020 Nov;34(11):2887-2897. doi: 10.1038/s41375-020-0921-y. Epub 2020 Jul 10.
Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by clonal proliferation of plasma cells and a heterogenous genomic landscape. Copy number and structural changes due to chromosomal instability (CIN) are common features of MM. In this review, we describe how primary and secondary genetic events caused by CIN can contribute to increased instability across the genome of malignant plasma cells; with a focus on specific driver genomic events, and how they interfere with cell-cycle checkpoints, to prompt accelerated proliferation. We also provide insight into other forms of CIN, such as chromothripsis and chromoplexy. We evaluate how the tumor microenvironment can contribute to a further increase in chromosomal instability in myeloma cells. Lastly, we highlight the role of certain mutational signatures in leading to high mutation rate and genome instability in certain MM patients. We suggest that assessing CIN in MM and its precursors states may help improve predicting the risk of progression to symptomatic disease and relapse and identifying future therapeutic targets.
多发性骨髓瘤(MM)是一种不可治愈的浆细胞恶性肿瘤,其特征是浆细胞的克隆性增殖和异质性基因组景观。由于染色体不稳定(CIN)导致的拷贝数和结构变化是 MM 的常见特征。在这篇综述中,我们描述了 CIN 引起的原发性和继发性遗传事件如何导致恶性浆细胞基因组的不稳定性增加;重点介绍了特定的驱动基因组事件以及它们如何干扰细胞周期检查点,从而促进加速增殖。我们还介绍了其他形式的 CIN,如染色体重排和染色体重组。我们评估了肿瘤微环境如何促进骨髓瘤细胞中染色体不稳定性的进一步增加。最后,我们强调了某些突变特征在导致某些 MM 患者高突变率和基因组不稳定性方面的作用。我们认为,评估 MM 及其前体状态中的 CIN 可能有助于提高预测进展为有症状疾病和复发的风险,并确定未来的治疗靶点。
Leukemia. 2020-7-10
Klin Onkol. 2024
Trends Cancer. 2020-10
Clin Lymphoma Myeloma Leuk. 2016-8
Cancers (Basel). 2021-11-26
Expert Opin Biol Ther. 2013-6-19
Signal Transduct Target Ther. 2021-10-7
Methods Mol Biol. 2025
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025-4-28
Br J Haematol. 2025-5
Cancer Pathog Ther. 2024-1-3
Mol Biomed. 2024-7-4
Nat Med. 2019-3-6
J Cancer Res Clin Oncol. 2018-8-24
Nat Commun. 2018-8-22
Cancer Discov. 2018-8-16
Nat Rev Clin Oncol. 2018-1-3